Next, the FDA has expanded the approved use of Wilate for routine prophylaxis in children younger than 6 years of age with von Willebrand disease. The plasma-derived von Willebrand factor and factor VIII replacement therapy was previously approved for older pediatric and adult patients. The expanded indication is supported by clinical data demonstrating that prophylactic treatment reduced bleeding episodes while maintaining a safety profile consistent with previous studies. The decision provides clinicians with an additional option for preventing spontaneous bleeding in one of the youngest patient populations affected by the inherited bleeding disorder.
Finally, the FDA has granted accelerated approval to Trutakna, or atacicept, making it the first therapy that simultaneously inhibits both B-cell activating factor, known as BAFF, and a proliferation-inducing ligand, or APRIL, for the treatment of IgA nephropathy. The approval is based on reductions in proteinuria, an established marker of kidney disease progression, with continued approval contingent on confirmatory clinical benefit. By targeting two key drivers of B-cell activation, the therapy introduces a new mechanism of action for patients with this chronic immune-mediated kidney disease.
Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.
Key Takeaways
- New glial biomarker data may help guide the next stage of clinical development for pepinemab in Alzheimer's disease.
- The FDA has expanded Wilate's indication to include routine prophylaxis for children younger than 6 years with von Willebrand disease.
- Trutakna becomes the first dual BAFF and APRIL inhibitor approved for IgA nephropathy, introducing a new targeted treatment approach.
